SAN JOSE, Calif., Sept. 12, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the inventor of its ovarian cancer CAR-T technology, Dr. Jose Conejo-Garcia, Senior Member of the Immunology Department at Moffitt Cancer Center, will be speaking at the Rivkin Center and American Association for Cancer Research (AACR) 14^th Biennial Ovarian Cancer Research Symposium. The symposium will include a seminar on immuno-oncology on Wednesday, September 28, 2022, at which Dr. Conejo-Garcia is an invited lecturer. 

During the presentation, Dr. Conejo-Garcia will discuss the CAR-T technology, which is an autologous cell therapy comprised of engineered T-cells that target the follicle stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries. Since the target is a hormone receptor, and the target-binding domain is derived from its natural ligand, this technology is also known as CER-T (Chimeric Endocrine Receptor T-cell) therapy, a new type of CAR-T. Dr. Conejo-Garcia will also discuss the ongoing Phase 1 clinical trial of this technology.

"I am excited to discuss our novel FSHR-mediated CAR-T technology at this seminar series and to share ideas and advance the field of ovarian cancer research," stated Dr. Conejo-Garcia. "Moffitt and Anixa have been working together to advance this ovarian cancer therapy and we are thrilled to have treated the first patient in our ongoing clinical trial. If this therapeutic approach is successful, this could enable a major shift in the overall treatment paradigm for ovarian cancer."

More information about the event may be found at: https://rivkin.org/symposia/ocrs/.

Anixa is a clinical-stage biotechnology company with a number of programs addressing cancer and infectious disease. Anixa's portfolio of therapeutics includes a cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and, with partner MolGenie GmbH, a COVID-19 program focused on compounds targeting the M^pro enzyme of SARS-CoV-2, which is largely conserved across all recently identified variants. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn and Facebook.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-ovarian-cancer-car-t-therapy-to-be-presented-at-the-rivkin-center--american-association-of-cancer-research-aacr-14th-biennial-ovarian-cancer-research-symposium-301621773.html

SOURCE Anixa Biosciences, Inc.